MARATTO

article · Zagazig University Medical Journal

Role Of Serum Hepcidin as A Diagnostic and Prognostic Marker For Sepsis among Critically ill Patients

2024Open accessZagazig University

Abstract

Background: In the last decade hepcidin which was previously known to have a significant role in iron metabolism, has gained attention as a possible marker of bacterial sepsis in adults. This research aimed to evaluate the role of hepcidin as a biomarker for diagnosis and prognosis ‎of sepsis among critically ill patients.Methods: In a cohort study, 62 emergency medical patients who were admitted to the ICU within 24 hours and were divided into two groups: those with sepsis (Group A) and those without (Group B). Hepcidin levels were measured using an ELISA kit, and patient assessments included SOFA, SAPS 3, and APACHE II scores.Results: Septic patients had significantly higher hepcidin than the non-septic patients (p<0.001). Hepcidin was a significant diagnostic marker for sepsis with sensitivity (91.89%) and specificity (70.97%) at cutoff point of 2.52 ng/ml with AUC was (0.922). Multivariate regression analysis revealed that alongside traditional sepsis markers, hepcidin and SAPS3 scores were independent predictors of mortality, with ORs of 2.09 (95% CI: 1.31–3.33, p=0.002) and 1.21 (95% CI: 1.04–1.4, p=0.01), respectively. Conclusion: Serum hepcidin, combined with clinical scoring systems, proves to be a reliable diagnostic tool for sepsis and could serve as a predictor of mortality in critically ill septic patients.

Research topics

  • Iron Metabolism and Disorders
  • Erythropoietin and Anemia Treatment

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/zumj.2024.285207.3354

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.